Nls pharmaceutics ltd. announces pricing of private placement of up to $1 million at a 15% premium to the market

Zurich , dec. 4, 2024 /prnewswire/ -- nls pharmaceutics ltd. (nasdaq: nlsp) (nasdaq: nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the pricing of a private placement offering consisting of the issuance and sale of up to 322,580 common shares only, par value chf 0.80 per share, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1.0 million, subject to shareholder approval.
NLSP Ratings Summary
NLSP Quant Ranking